The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...
Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the 340B Drug Pricing Program. The complaint claims Amgen bypassed federal ...
In 2021, we provided an overview of multiple federal lawsuits challenging the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) enforcement of the ...
The 340B Drug Pricing Program enacted in 1992 requires pharmaceutical manufacturers participating in the Medicaid program to provide statutorily defined discounts on "covered outpatient drugs" ...
As the new year begins, gyms are crowded, dietitians’ schedules are packed and dental chairs are filled — signs that Americans are embracing their New Year’s resolutions to focus on health. Alongside ...
6d
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy?
Sagebrush Health Services has filed a lawsuit in California state court accusing Amgen of unlawfully cutting off 340B discounted drug sales to its Nevada clinics and reclaiming at least US$7,000,000 ...
The 340B Drug Pricing Program (340B) is a cornerstone of equitable healthcare in the U.S. For more than 30 years, it has ensured that drug manufacturers provide discounted medications to qualifying ...
The 340B Drug Pricing Program is a federal lifeline for vulnerable and underserved communities across the U.S., and its importance in Orlando is profound. Created to allow health-care safety-net ...
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results